Chimeric antigen receptors in the brain: Can we tackle glioblastoma with engineered NK cells?
作者信息
Roth Patrick
机构信息
University Hospital Zurich and University of Zurich, Department of Neurology and Brain Tumor Center, Zurich, Switzerland.
出版信息
Neuro Oncol. 2023 Nov 2;25(11):2072-2073. doi: 10.1093/neuonc/noad131.
Abstract
摘要
相似文献
1
Chimeric antigen receptors in the brain: Can we tackle glioblastoma with engineered NK cells?大脑中的嵌合抗原受体：我们能用工程化自然杀伤细胞攻克胶质母细胞瘤吗？
Neuro Oncol. 2023 Nov 2;25(11):2072-2073. doi: 10.1093/neuonc/noad131.
2
Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma.用于胶质母细胞瘤的抗原特异性嵌合抗原受体KHYG-1细胞的开发。
Anticancer Res. 2021 Apr;41(4):1811-1819. doi: 10.21873/anticanres.14947.
3
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.嵌合抗原受体修饰的自然杀伤细胞治疗胶质母细胞瘤：将固有效应细胞转化为癌症免疫治疗的精准工具。
Front Immunol. 2019 Nov 14;10:2683. doi: 10.3389/fimmu.2019.02683. eCollection 2019.
4
Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.工程嵌合抗原受体-自然杀伤细胞用于癌症免疫治疗。
Immunotherapy. 2020 Jun;12(9):653-664. doi: 10.2217/imt-2019-0139. Epub 2020 May 21.
5
Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy.自然杀伤细胞和嵌合抗原受体修饰 NK-92 细胞在肿瘤免疫治疗中的当前应用。
Int J Mol Sci. 2019 Jan 14;20(2):317. doi: 10.3390/ijms20020317.
6
KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells.KHYG-1 细胞带有 EGFRvIII 特异性嵌合抗原受体，在源自胶质母细胞瘤样细胞的皮下肿瘤中诱导出一种假性进展样特征。
Anticancer Res. 2020 Jun;40(6):3231-3237. doi: 10.21873/anticanres.14304.
7
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.嵌合抗原受体表达的自然杀伤细胞用于癌症的免疫治疗。
Front Immunol. 2018 Feb 15;9:283. doi: 10.3389/fimmu.2018.00283. eCollection 2018.
8
9
Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies.嵌合抗原受体自然杀伤细胞疗法在克服难治性血液系统恶性肿瘤方面的最新进展。
Hematol Oncol. 2021 Feb;39(1):11-19. doi: 10.1002/hon.2802. Epub 2020 Sep 21.
10
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.嵌合抗原受体自然杀伤 (CAR-NK) 细胞设计与工程在癌症治疗中的应用。
J Hematol Oncol. 2021 May 1;14(1):73. doi: 10.1186/s13045-021-01083-5.
本文引用的文献
1
Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma.嵌合抗原受体 T 细胞靶向 CD317 作为一种针对胶质母细胞瘤的新型免疫治疗策略。
Neuro Oncol. 2023 Nov 2;25(11):2001-2014. doi: 10.1093/neuonc/noad108.
2
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.在复发性胶质母细胞瘤患者中，经 HER2 靶向嵌合抗原受体工程化的自然杀伤细胞颅内注射。
Neuro Oncol. 2023 Nov 2;25(11):2058-2071. doi: 10.1093/neuonc/noad087.
3
Advances in NK cell therapy for brain tumors.脑肿瘤自然杀伤细胞疗法的进展。
NPJ Precis Oncol. 2023 Feb 15;7(1):17. doi: 10.1038/s41698-023-00356-1.
4
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.CAR T 细胞杀伤需要 IFNγR 通路，但在实体瘤中而不是在液体肿瘤中。
Nature. 2022 Apr;604(7906):563-570. doi: 10.1038/s41586-022-04585-5. Epub 2022 Apr 13.
5
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.小鼠CAR-T细胞的优化基因工程揭示了共表达IL-15的有益效果。
J Exp Med. 2021 Feb 1;218(2). doi: 10.1084/jem.20192203.
6
Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma.用于特异性有效靶向胶质母细胞瘤的氯毒素导向嵌合抗原受体T细胞。
Sci Transl Med. 2020 Mar 4;12(533). doi: 10.1126/scitranslmed.aaw2672.
7
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.胶质母细胞瘤的免疫治疗：过继性 T 细胞策略。
Clin Cancer Res. 2019 Apr 1;25(7):2042-2048. doi: 10.1158/1078-0432.CCR-18-1625. Epub 2018 Nov 16.
8
NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.化疗和放疗对神经胶质瘤的 NKG2D 依赖性抗肿瘤作用。
Clin Cancer Res. 2018 Feb 15;24(4):882-895. doi: 10.1158/1078-0432.CCR-17-1766. Epub 2017 Nov 21.
9
CAR T-Cell Therapies in Glioblastoma: A First Look.嵌合抗原受体 T 细胞疗法治疗胶质母细胞瘤：初探。
Clin Cancer Res. 2018 Feb 1;24(3):535-540. doi: 10.1158/1078-0432.CCR-17-2871. Epub 2017 Nov 20.
10
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.单次外周输注靶向表皮生长因子受体III型变异体（EGFRvIII）的嵌合抗原受体（CAR）T细胞可介导抗原缺失，并在复发性胶质母细胞瘤患者中诱导适应性耐药。
Sci Transl Med. 2017 Jul 19;9(399). doi: 10.1126/scitranslmed.aaa0984.
Zotero 插件